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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
1.1 DIABETES MELLITUS 
The term diabetes mellitus describes a metabolic disorder of multiple etiology 
characterized by chronic hyperglycemia with disturbances of carbohydrates, fat and protein 
metabolism resulting from defects in insulin secretion, insulin action or both. Diabetes means 
that your blood sugar is too high. Your blood always has some sugar in it because the body needs 
sugar of energy to keep you going. But too much sugar in the blood is not good for your health. 
Diabetes is the disorder of metabolism the way our body use the digested food for growth and 
energy. Most of the food we eat is broken down by the Digestive juices into a simple sugar 
called glucose. which is the main source of fuel for the body(Vigneri R et al., 1987). 
Diabetes mellitus is a group of syndromes characterized by hyperglycemia. The World 
Health Organization (WHO) has designated diabetes mellitus as an epidemic, although it is a 
non-infectious disease. Nearly 203% of the world’s population is estimated to be suffering from 
this disease, with an increasing trend of 4-5% every year (Allison DB et al., 1999).  
After digestion, the glucose passes into our bloodstream where it is available for body 
cells to use for growth and energy. For the glucose to get into the cells, insulin must be present. 
Insulin is a hormone produced by the pancreas, a large gland behind the stomach. When we eat, 
the pancreas is supposed to automatically produce the right amount of insulin to move the 
glucose from our blood into our cells. If your body doesn’t make enough insulin or the insulin 
doesn’t work right, the sugar cannot get into the cells. It stays in the blood; this makes your 
blood sugar level high and causing you to have diabetes. As a result, glucose builds up in the 
blood, overflow into the urine, and passes out of the body, Thus the body loses its main source of 
fuel even through the blood contains large amounts of glucose(Vigneri R et al., 1987). 
          Diabetes is a metabolic disorder and metabolism is the way by which the body uses 
digested food for growth and energy. Glucose is the end product of our food after all the 
processes of ingestion, digestion, assimilation and absorption which means anything that is 
consumed, finally breaks down into glucose, once digestion is over, next comes the process 
known as the assimilation. After the digestion process, the glucose that passes into the 
bloodstream needs to be utilized by cells for growth and energy. To aid the glucose getting into 
 
 
the cells, we require a hormone called the insulin a hormone produced by the pancreas of islets 
of Langerhans (Narayan KM et al., 2003).  
1.2 CLASSIFICATION 
      The first widely accepted classification of diabetes mellitus was published by WHO in 1980 
and modified from in 1995. 
 Type 1 or Insulin Dependent Diabetic Mellitus (IDDM) or juvenile onset diabetes. 
 Type II or Non Insulin Dependent Diabetes Mellitus (NIDDM) or maturity onset 
diabetes. 
 Gestational Diabetes (diabetes of pregnancy) 
1.2.1 Type 1 or Insulin Dependent Diabetic Mellitus (IDDM) or juvenile onset diabetes: 
Type-I or Insulin dependent diabetes mellitus or juvenile onset diabetes mellitus which is 
due to the destruction of pancreatic b cells, it causes are unknown but in some cases due to viral 
infection and current research indicates that it may also be due to auto immunity. Islets cell auto 
antibodies are present in the serum of 90% newly diagnosed cases. Such antibodies are directed 
against several cell components including cytoplasm and membrane antigens or against insulin 
itself (Daneman D et al., 2006). 
    1.2.2 Type II or Non Insulin Dependent Diabetes Mellitus (NIDDM) or maturity onset 
diabetes: 
Type-II or Non insulin Dependent Diabetes Mellitus or Adult onset Diabetes Mellitus 
which is due to the impairment of insulin release and basal secretion of insulin. In this case, 
insulin resistance occurs due to the defect in the tissue response to insulin caused by the 
defective insulin receptors on the target cells.   Type-II diabetes is the most common form of 
diabetes accounting for 90-95% of cases. In Type-II diabetes, the body does not respond properly 
to insulin, a condition known as insulin resistance (Goldfine A et al., 2001). 
 
 
 
 
1.2.3Gestational Diabetes: 
Gestational diabetes is a condition in which some women develop gestational diabetes in 
late pregnancy. Although this form of diabetes usually disappear after the delivery, women who 
have had gestational diabetes have a 40 to 60 percent chance of developing Type-II diabetes 
within 5 to 10 years. Maintaining a reasonable body weight and being physically active may help 
prevent development of Type-II diabetes. About 5% of pregnant women develop a form of Type-
II diabetes, usually temporary, in their third trimester called gestational diabetes (American 
Diabetes Association, 2005). 
1.3 EPIDEMIOLOGY 
Diabetes mellitus became the common non-communicable disease in both developing 
and developed countries compared to developing countries like India and it became epidemic 
disease. On the basis of number of epidemiological studies, it has been reported that in India 
more than fifty million of people suffering with diabetes mellitus   next follows China with 
nearly forty four million people.India leads the world with highest number of diabetic subjects 
earning the dubious distinction of being termed them ‘Diabetes capital of the world’.  
Diabetes Atlas 2006 published by the international Diabetes federation, the number of 
people with diabetes mellitus in India currently around 409 million and is expected to rise to 69.9 
million by 2035 unless essential preventive steps are taken. They so called ‘ Asian India 
Phenotype’ refers to certain unique clinical and biochemical abnormalities in Indians which 
include increased insulin resistance, greater abdominal adiposity like higher waist circumference 
a despite lower body mass index, and higher high sensitive C reactive protein, lower adiponectin 
levels.  
The microvascular and macrovascular impediment caused by the diabetes mellitus like 
diabetic neuropathy, nephropathy, retinopathy, cardiovascular diseases and foot amputation are 
also became the major health in 21
st 
century. WHO estimated that, in 1995 the number of people 
with diabetes anticipates rising from current estimate of     150-220 million in 2010 and 300 
million in 2025. 
 
 
 
1.4 PATHOPHYSIOLOGY 
1.4.1 Type-I Diabetes: 
 Type I diabetes mellitus (Insulin-Dependent Diabetes Mellitus, IDDM ) is due to 
destruction of pancreatic beta cells.  The cause of beta cells destruction in type-I diabetes is 
unknown. A few cases have followed viral infections, most commonly with coxsakie virus B or 
mumps virus. Autoimmunity is believed to be the major mechanism involved. Sensitized T 
lymphocytes with activity against beta cells have also been demonstrated in some patients. 
    The etiology of Type-II diabetes mellitus (Non-Insulin-Dependent Diabetes Mellitus, 
NIDDM) is even less clearly understood. Two factors have been identified: 
a) Impaired insulin release-basal secretion of insulin is often normal, but the rapid release 
of insulin follows a meal is greatly impaired, resulting in failure of normal handling of 
a carbohydrates load. 
b) Insulin resistance-a defect in the tissue response to insulin is believed to play a major 
role. 
This phenomenon is called insulin resistance and is caused by defective insulin receptors 
on the target cells. Insulin resistance occurs in association with obesity and pregnancy. 
1.4.2 Type-II Diabetes 
 1.4.2.1 Pancreas 
  The pancreas is a pale grey gland weighing about 60 grams and is about 12 to 15 cm long 
and situated in the epigastric and left hypochondriac regions of the abdominal cavity. It consists 
of a broad head, a body and a narrow tail. The head lies in the curve of the duodenum, the body 
behind the stomach and the tail in front of the left kidney and just reaches the spleen. The 
pancreas is both an exocrine and endocrine gland. 
 
 
 
 
1.4.2.2 Functions of Pancreas 
 The enzymes secreted by the exocrine tissue in the pancreas help in breaking down 
carbohydrates, proteins, fats and acids, in the duodenum. When they enter into the 
duodenum, they get activated, the exocrine tissue also secretes bicarbonates to neutralize 
stomach in the duodenum. 
 The functions of the endocrine tissue in the pancreas is to secrete the hormones insulin 
and glucagon.
.
 
 
Figure No.1. Pancreas and islet of langerhans
 
1.4.2.3 Islets of Langerhans 
     Islets of Langerhans is the insulin-producing tissue which consists of groups of specialized 
cells in the pancreas that make secrete hormone named after the German pathologist Paul 
Langerhans (1847- 1888), who discovered in 1869.These cells sit in group that Langerhans 
likened to little islands in the pancreas the pancreatic islet includes four types of hormones 
secreting cells : 
 
 
 Alpha cells: - composing about 20% of pancreatic islet cells, it secretes glucagon which 
rises blood glucose level. 
 Beta cells: - These secretes insulin which reduces the blood glucose level, constitute 
about 70% pancreatic islet cells (Tortora GJ et al., 2005). 
 Delta cells: - constitute the 5% of pancreatic islets cells, these secretes somatostatin 
which provides local inhibitory regulation of insulin and glucagon release within the islet. 
 F cells: - constitute the remainder of pancreatic islet cells, it secrete pancreatic 
polypeptide, which inhibit the secretion of somatostatin and pancreatic digestive enzyme 
(Tortora GJ et al., 2005). 
 
 
 
Figure No.2. Structure of islet of langerhans of pancreas 
 
 
 
1.4.2.4 Insulin  
Insulin is a polypeptide hormone produced by the b cells of islets of Langerhans of 
pancreas. It has profound influences on the metabolism of carbohydrate, fat and protein. Insulin 
is considered as anabolic hormone, as it promotes the synthesis of glycogen, triacylglycerol and 
proteins. This hormone has been implicated in the development of diabetes mellitus. Human 
insulin (Mol. wt. 5,734) contains 51 amino acids, arranged in to polypeptides chains. The chain 
A has 21 amino acids while B has 30 amino acids. Both are held together by two inter chain 
disulfide bridges. The synthesis of insulin involves two precursors, namely pre proinsulin with 
108 amino acids and pro insulin with 86 amino acids. 
 
Figure No.3. Structure of Insulin 
 
 
 
 
 
Insulin Mechanism of Action 
Insulin binds to specific receptors on the surface of its target cells. The receptors are a 
large transmembrane glycoprotein complex consisting of two alpha and beta subunits. The alpha 
sub units are entirely extra cellular and each carries an insulin-binding site, where as the beta 
subunits are membrane proteins with tyrosine kinase activity. This activity is suppressed by the 
alpha sub units, but insulin binding causes a conformational change that depresses (activates) the 
tyrosine kinase activity of the beta subunits, which act on each other (auto phosphorylation) and 
on other target proteins. 
 
 
Figure No.4. Mechanism of action of insulin 
 Insulin reagent substrate (IRS) also auto phosphorylation takes place, further which will 
activates the protein kinase enzyme. This enzyme responsible for all cellular functions. At 
concentration of insulin that produces maximum effects, less than 10% of the receptors are 
occupied. Occupied receptors aggregate in to clusters, which are subsequently internalized in 
vesicles, resulting in down regulation. Internalized insulin is degraded in lysosomes, but the 
receptors are recycled to the plasma membrane (Rang HP et al., 2006). 
 
 
 
 
a) Production of insulin  
        Insulin is a hormone which is synthesized in the beta cells of the islets of Langerhans. Its 
signal peptide is removed in the endoplasmic reticulum and then packed into secretory vesicles 
in the Golgi.  It is folded in its nature and locked in this confirmation by the formation of two 
disulfide bonds. In normal persons, insulin is produced by the body in response to the rice in 
blood glucose level.  
 Apart this, spurts of insulin produced throughout the day and night, to look after the body 
resting needs for insulin and ensure that the cells can take up glucose. There are numerous 
hyperglycemic hormones untreated disorders associated with insulin, generally leads to severe 
hyperglycemia and a shortened life span. 
 
Figure No.5. Production of insulin 
Insulin is synthesized from the proinsulin molecule by the proteolytic enzymes, known as 
prohormone convertase (PC1  and PC2), as well as the Exo protease carboxypeptidase E. these 
modification of proinsulin remove the center part of the molecule from the C- and  N- terminal 
ends of proinsulin. The remaining Polypeptides (51 amino acids), B and A chains are bound each 
other by disulfide bond. 
 
 
 
b) Insulin secretion  
Rising of glucose levels inside the pancreatic beta cells trigger the release of insulin. 
Glucose is transported in to the beta cell by Type 2 glucose transporters (GLUT2). The initial 
step in glucose metabolism in the phosphor relation of glucose to produce glucose 6-phosphate. 
This is catalyzed by glucokinase, which is the rate limiting step in glycolysis, and it effectively 
traps glucose inside the cell.  
The glucose 6- phosphate is subsequently undergoing oxidation to form adenosine 
triphosphate (ATP), It is produced in the mitochondria. The increase in the ATP than ADP ratio 
closed ATP gated potassium channels in the beta cell membrane. Positively charged potassium 
ions (K
+
) are now prevented from leaving in the beta cell.  
This rise in positive charge inside in the beta cell causes the depolarization. Voltage-
gated calcium channels open and allowing calcium ions (Ca
2+
) to pass in to the cell. The increase 
in intracellular calcium ion concentration triggers the insulin secretion via exocytosis. 
 
Figure No.6. Insulin Secretion. 
 
 
 
 
 
Factors affecting insulin secretion:- 
 Epinephrine is the highly effective inhibitor of insulin secretion. 
 Starvation reduces insulin secretion. 
 Magnesium also inhibits insulin secretion. 
 Vagotomy reduces insulin secretion. 
c) Insulin resistance 
    Insulin resistance is a condition at which body does not able to utilize the insulin due to lack of 
insulin receptors. Then normally body produced insulin is not sufficient to maintain blood 
glucose level at normal range. So extra insulin may be needed to break down glucose in order to 
release energy. In about 1/3 of the cases blood cells resist to even high level of insulin. High 
triglycerides and low HDL, cardiovascular diseases hypertension and other such abnormalities 
are stimulant the insulin resistance. It is thus believed that diabetes and other problems go hand 
in hand. 
 
Figure No.7. Insulin Resistance 
 
 
 
Insulin resistance can also appear in the following conditions like the obesity, metabolic 
syndrome, severe illness, pregnancy, infection and stress during steroid use. Insulin resistance 
initially starts with hyperglycemia and over time, hyperglycemia leads to diabetes Type-II (Eva 
toamset al., 2002). 
1.5. Risk factors of diabetes. 
a) Heredity or inherit traits: it is due to passing of genes from one generation to another, a 
person can inherit diabetes. It depends up on closeness of blood relationship as mother is 
diabetic, risk is 2 to 3% father is diabetic, then the risk is more than the previous case and 
if both the parents are diabetic, the child has higher risk for diabetes. 
b) Age: increased age is a factor which gives more possibility than in younger age. This 
disease may occur at any age, but 80% of cases occur after 50 year, incidence increase 
with the age factor. 
c) Poor diet (malnutrition related diabetes): improper nutrition, low protein and fiber 
intake, high energy intake of refined products are the expected reasons for developing 
diabetes mellitus. 
d) Obesity and fat distribution: being overweight indicates increased insulin resistance 
that is if body fat more than 30%, BMI 25+, waist grith 35 inches in women or 40 inches 
in males. 
e) Sedentary lifestyle: people with more sedentary lifestyle are prone to diabetes, when 
compared to those who exercise thrice a week, are at low risk of falling prey to diabetes. 
f) Stress: either physical injury or emotional disturbance is frequently blamed as the initial 
cause of the diabetic. Any disturbance in corticosteroid or ACTH therapy may lead to 
clinical signs of the diabetes. 
g) Drug induced: clozapine (Clozaril), olanzapine (Zyprexa), risperidone                  
(Risperdal), quetiapine (Seroquel) and ziprasidone (Geodon) are known to induce this 
lethal disease. 
 
 
h) Infection: some of the staphylococci is suppose to be responsible factor for infection in 
pancreas. 
i) Gender: diabetes is commonly seen in elder persons particularly males but, strongly in 
women and those females with multiple pregnancy or suffering from (PCOS) polycystic 
ovarian syndrome. 
j) Hypertension: hypertension had been reported in many studies that there is direct 
relationship between high systolic pressure and diabetes.  
1.6 Signs and symptoms of diabetes 
 The most common symptoms of DM are those of hyperglycemia an osmotic diuresis 
caused by glycosuria leading to urinary frequency, polyuria, and polydipsia that may 
progress to orthostatic hypotension and dehydration. Severe dehydration causes 
weakness, fatigue, and mental status changes.  
  Hyperglycemia can also cause weight loss, nausea and vomiting, and blurred vision, 
and it may predispose to bacterial or fungal infections.  
 Patients with Type I DM typically present with symptomatic hyperglycemia and 
sometimes with diabetic ketoacidosis. 
 In some patients, hyperosmotic coma occurs initially, especially during a period of 
stress or when glucose metabolism is further impaired by drugs such as corticosteroids 
(King H et al., 1998). 
1.6.1 Symptoms of Type I diabetes may include: 
 Increased thirst and urination 
 Constant hunger 
 Weight loss 
 Blurred vision 
 Extreme tiredness 
 
 
1.6.2 Symptoms of Type II diabetes may include: 
 Feeling tired or ill 
 Frequent urination (especially at night ) 
 Unusual thirst 
 Weight loss 
 Blurred vision 
 Slow healing of sores 
 Having dry itchy skin 
 Losing feeling in the feet or having tingling in the feet  
1.7 Drugs for Diabetes Mellitus 
1) Sulfonyl Ureas: 
First generation: 
 Tolbutamide 
 Chloropropamide 
Second generation: 
 Glibenclamide 
 Glipizide 
 Gliclazide 
 Glimepride 
 
 
 
 
2) Biguanides: 
 Phenformin 
 Metformin 
3) Meglitinide analogues: 
 Repaglinide 
 Nateglinide 
4) Thiazolidinediones: 
 Rosiglitazone 
 Pioglitazone 
5) Glucosidase inhibitors: 
 Acarbose 
 Miglitol 
 The following are the 2006 WHO recommendation for the diagnostic criteria and 
intermediate hyperglycemia. 
1. Measurement of blood glucose levels 
2. Oral glucose tolerance test (OGTT) 
3. Glycated hemoglobin  levels (HbAlc)  
 
 
 
 
 
 
1.8 Diabetic Complications 
 
 
 Figure No.8. Complication of Diabetes  
Microvascular complications of diabetes are a significant are a cause of morbidity, 
persistent hyperglycemia is the important cause of the microvascular complications which are 
highly specific for diabetes.  
 Retinopathy with potential loss of vision. 
 Nephropathy leading to kidney failure. 
 Peripheral neuropathy leading to pain, foot ulcers and limb ampulsion. 
 Autonomic neuropathy causing gastrointestinal, genitourinary, cardiovascular 
symptoms and sexual dysfunction. 
 
 
 
Diabetic Retinopathy 
Diabetic retinopathy occurs in 3/4
th
 of persons with more than 15 years of diabetes. 
Diabetic retinopathy is diagnosed by the appearance of retinal lesions of eye which increasing 
severity, Culminating in the growth of new vessels. Retinal vessels of eye can leak at any stage 
of retinopathy and produce macular edema with potentially irreversible loss of central vision. 
Excessive retinal revascularization, vitreous hemorrhage, and increased levels of VEGF 
can lead to fibrosis and retinal detachment. Application of pan-retinal laser photocoagulation has 
dramatically reduced the rate of blindness in patients with diabetic retinopathy. 
Diabetic Neuropathy  
 About 50% of diabetic patients have some degree of neuropathy which present in either 
polyneuropathy or a mono neuropathy. Diabetic neuropathy is thought to occur both from direct 
hyperglycemia-induced damage to the nerve parenchyma and from neuronal ischemia brought 
about indirectly by hyperglycemia induced decreases in neurovascular flow. Diabetic neuropathy 
and decreases in neuronal function were prevented by oxygen supplementation and by the 
administration of vasodilator agents. 
Diabetic Nephropathy 
 Diabetic nephropathy is characterized by glomerular hemodynamic abnormalities  in 
kidney that result in glomerular hyper filtration, leading to glomerular damage as evidenced by 
micro-albuminurea. As glomerular function of kidney continuous to abnormal. Over proteinuria, 
decreased glomerular filtration rate, and at the end stage renal failure will result.  
Angiotensin-converting enzyme inhibitors and angiotensin receptors blockers is effective 
in delaying the progression of clinical diabetic nephropathy. 
 
 
 
 
 
 
Macrovascular 
 Macrovascular complications are the main cause of mortality. Persistent hyperglycemia 
may contribute to macrovascular complications of diabetes. 
 Coronary heart disease is the major cause of death for patients with diabetes. 
 Peripheral vascular disease  
 Cerebrovascular disease. 
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2. PLANT PROFILE 
      
Figure.No.9 Whole plant of Premna corymbosa   Figure.No.10 Roots of Premna corymbosa 
2.1 Distribution: 
Throughout india in the plains. 
2.2 The plant: 
      A large shrub or a small tree up to 9cm in height with yellowish lenticellate bark, spinous 
large branches and yellowish brown woody aromatic root; leaves simple, opposite, sometimes 
whorled, elliptic-ovate, membranous when young, coriaceous when mature, entire or irregularly 
toothed, primary lateral nerves 4-6 pairs; flowers small, greenish yellow or greenish white with a 
strong disagreeable odour in corymbiform cymose panicles; fruits globose drupes, black when 
ripe with the persistent saucer-shaped calyx surrounding its base. 
2.3 Taxonamy: 
Scientific Name         : Premna corymbosa Rottl. 
Synonym                     :  Premna serratifolia Linn. 
Family                         : Verbenaceae. 
Common names          : Malayalam: Munna. 
Tamil   : Munnai, pasumunnai. 
Telugu   : Padmaka. 
 
 
 
2.4 Parts used: 
     Roots and leaves. 
2.5 Properties and uses: 
        The roots are astringent, bitter, acrid, sweet, thermogenitic, anodyne, anti-inflammatory, 
alexeteric, alterant, expectorant, depurative, diagestive, carminative, stomachic, laxative, 
febrifuge, antibacterial and tonic. 
They are useful in vitiated conditions of vata and kapha, neuralgia, inflammations, 
cardiac disorders, hepatopathy, cough, asthma, bronchitis, leprosy, skin diseases, dyspepsia, 
flatulence, colic, anorexia, constipation, haemorrhoids, fever, diabetes and general debility. 
The leaves are stomachic, carminative and galactagogue, and are useful in rheumatalgia, 
neuralgia, haemorrhoids and tumours. 
2.6 Chemical constituents: 
       The plant is reported to contain Alkaloids, Tannins, Cardiac glycosides and traces of 
flavonoids etc. 
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3. REVIEW OF LITERATURE 
 
 Karthikeyan M et al., (2008) reported that the Premna corymbosa is a common  plant, it 
is used in various ayurvedic preparations. The aim of the present study is to evaluate the 
anti hyperlipidemic activity of Premna corymbosa leaves in CCl4 induced hepatic 
damaged rats. Liver was damaged in wistar rats of both sex by intraperitoneal injection of 
CCl4 in the concentration of 1 ml/kg body weight for every 72 h. The ethanolic extract of 
Premna corymbosa leaves were administrated at thedoses of 200 & 400 mg/kg body 
weight, p.o., daily for 14 days. The anti hyperlipidemic effect of the ethanolic extract was 
assessed by the assay of the biochemical parameters like serum triglycerides (STG), 
serum total cholesterol (STC) and Very low density lipoprotein cholesterol (VLDL-c).                    
The ethanolic extract, significantly (p<0.01) restoredthe levels of biochemical parameters 
as compared to normal. The results obtained shows that the ethanolic extract of                
Premna corymbosa has anti hyperlipidemic property. 
 
 Jayakar B et al., (2010) evaluated that the ethanolic and aqueous extracts 
of Premna corymbosa (Burm.F.) Rottl (Verbenacea) in normal and streptozotocin (STZ) 
induced diabetic rats. Diabetes was induced by intra peritoneal (i.p) injection of 
streptozotocin (50 mg/kg) in adult male albino Wistar rats. Blood glucose levels were 
determined after oral administration of a dose of P. corymbosa (400 mg/kg b. wt) in 
diabetic groups. Blood glucose levels were determined on 0, 7th, 14th and 21st day after 
oral administration of ethanolic and aqueous extracts of P. corymbosa (400 mg/kg) 
respectively and standard drug (glibenclamide) exhibited (500 µg/kg) in diabetic rats. 
The effect of extracts of P. corymbosa on blood glucose levels and serum lipid profile 
like Total cholesterol, triglycerides, phospholipids, low density, very low density and 
high density lipoprotein were measured in the diabetic and non diabetic rats. There was 
significant reduction in Total cholesterol, LDL cholesterol, VLDL cholesterol and 
improvement in HDL cholesterol in diabetic rats. These results indicate that P. 
corymbosa possesses a hypoglycemic effect. 
 
 
 
 Deepa k et al., (2010) investigated that the hepatotoxicity was induced in wistar rats of 
both sexes by intraperitoneal injection of CCl4, 1 mL/kg body weight for every 72 h. The 
ethanolic extract of Premna corymbosa leaves were administrated at doses of 200 & 400 
mL/kg body weight, p.o. daily for 14 days. The hepatotoxicity and its prevention was 
assessed by serum markers like serum alkaline phosphatase (SALP), serum triglycerides 
(STG), serum total protein (STP), serum cholesterol (SC), and liver wet weight and 
histopathological studies of the liver. Results in treatment with the ethanolic extract, the 
toxic effect of CCl4was controlled significantly (P < 0.01) by restoration of the levels of 
biochemical parameters as compared to normal and standard drug silymarin treated 
groups. The liver weight was reduced by the ethanolic extract treated groups. The 
histopathology of the liver sections evidenced the hepatoprotective activity. 
 
 M Karthikeyanet al., (2011) reported that the acute toxicity study, a single dose of 
PCEE of 2000 mg/kg body weight, p.o. was administered and observed for 48 h. In acute 
models as egg albumin induced paw edema and chronic model as cotton pellet methods 
was followed. Results in acute models, egg albumin induced paw edema PCEE 
significantly (P<0.01) inhibited the edema formation. In chronic model, cotton pellet 
induced granuloma formation in rats PCEE significantly (P<0.01) reduced the granuloma 
formation with percentage inhibition of 35.17% and 50.38 % respectively. 
 
 ThamizhSelvam N et al., (2015) evaluated that the hyperlipidemia is one of the greatest 
risk factors contributing to atherosclerosis and occurrence of coronary heart diseases. 
Hence hypolipidemic drugs are extensively used as prophylactic agents for preventing 
such atherosclerosis induced disorders. As synthetic drugs have lot of side effects, the 
focus on herbal drugs is increasing present day. SPHAG is a poly herbal formulation 
developed by the combination of aqueous extracts of plants Solanum nigrum, Premna 
corymbosa, Holarrhena pubescens, Alstonia scholaris and Gymnema sylvestre. The 
experiment was carried out in Wistar albino rats comprised of five groups such as 
Healthy Control, Disease Control, Drug Control, SPHAG Low Dose and SPHAG High 
Dose. The study was conducted for a period of 25 days by daily single dose of test extract 
through oral administration. At the end of the experiment, lipid profile, Biochemical 
 
 
profiles were evaluated. The study demonstrated the Hypolipidemic activity of SPHAG 
and the efficacy was dose dependent. The phytochemical studies showed the presence of 
phytoconstituents like alkaloids, flavonoids and phenols. 
 
 NarmadhaRajasekaran et al., (2012) investigated that the in-vivo antioxidant activity of 
ethanolic extract Premna corymbosa (Rottl.) root against streptozotocin induced 
oxidative stress in different organs (liver, kidney, brain, heart and pancreas) of rats. 
Ethanolic extract of Premna corymbosa (Rottl.) root was administered orally (200 mg/kg 
body weight) and the effect of extract on enzymatic antioxidants like superoxide 
dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione-S-
transferase (GST) and polyphenol oxidase (PPO), non enzymatic like vitamin C, vitamin 
E and glutathione. Lipid peroxidation likeasal, ascorbate and peroxide induced lipid 
peroxidation were also estimated. Glibenclamide was used as standard reference drug. A 
significant increase in the activities of superoxide dismutase, catalase, glutathione 
peroxidase, glutathione-Stransferase and reduced glutathione were observed in different 
organs of diabetic rats on treatment with 200 mg/kg body weight of Premna corymbosa 
(Rottl.) root extract and glibenclamide for 30 days treatment. Both the treated groups 
showed significant decrease in lipid peroxidation, suggesting its role in protection against 
lipid peroxidation induced membrane damage. Premna corymbosa (Rottl.) possesses 
antioxidant potential which may be used for therapeutic purposes mainly in the 
prevention of oxidative damage that occur during diabetes. 
 
 Rajni Yadav et al., (2016) reported that the Ethanolic extract of                                         
Premna corymbosa Rottl. Leaves (EEPC) were evaluated for anti-cancer activity against 
Ehrlich ascites carcinoma (EAC) bearing swiss albino mice and for the present anticancer 
study we used two concentration of ethanolic extract of Premna corymbosa Rottl. 
(EEPC) in the dose of 100 mg/kg and 200 mg/kg in 1% carboxy methyl cellulose (CMC) 
and were given orally.Result: The leaf of Premna corymbosa Rottl was selected for the 
study, on the basis of ethano botanical information which reveals its uses against one of 
the most hazardous disease cancer which shown significant response. Conclusion: The 
 
 
leaves of Premna corymbosa Rottl. Has been studied to compare and give detailed 
reports on pharmacological studied on it. 
 
 M Karthikeyan et al., (2010) evaluated that the acute toxicity and anti nociceptive 
activity of an ethanol extract of Premna corymbosa in animal models. In the acute 
toxicity study, the ethanolic extract showed no clinical signs and mortality of the animals 
and was found to be safe. In the acetic acid-induced writhing model, the ethanolic extract 
at a dose of 200 or 400 mg kg(-1) body weight significantly (p < .01) inhibited the 
writhing response by 42.57% and 54.67%, respectively. In the hot plate test, the extract 
produced a significant         (p < .01) increase in latency with 34.50% and 51.08% of 
protection in a dose-related manner. This study has established the analgesic properties of                        
Premna corymbosa (Burm.f.) Rottl. And Willd. The beta-sitosterol or luteolin present in 
the ethanolic extract may contribute the antinociceptive activity of                            
Premna corymbosa. 
 
 M Karthikeyan et al., (2010) Premna corymbosa (Burm.f.) Rottl. & Willd. 
(Verbenaceae) is a small tree used in traditional medicine for rheumatic disorders and it is 
the one of the ingredient in many ayurvedic preparations available in the market for 
inflammatory disorder uses. The aim of this work was to evaluate the acute toxicity and 
anti-arthritic activity of Premna corymbosa ethanolic extract (PCEE) in experimental 
animals. In the acute toxicity study, a single dose of PCEE, 2000 mg kg (-1) body weight 
p.o., was administered. The animals observed for 48 h showed no clinical signs, no 
mortality, and the extract was found to be safe. To evaluate the anti-arthritic activity of 
PCEE in Complete Freund's Adjuvant (CFA)-induced arthritis in rats were conducted. 
The results indicated that the long-term treatment significantly (p<.01) suppressed the 
development of chronic arthritis induced by CFA. This study established the anti-arthritic 
activity of Premna corymbosa leaves. 
 
 
 
 
 
 Mahmud ZA et al., Premna esculenta Roxb. (family-Verbenaceae) is a shrub used by 
the ethnic people of Chittagong Hill Tracts of Bangladesh for the treatment of 
hepatocellular jaundice. The present study was done to evaluate the hepatoprotective and 
the in vivo antioxidant activity of ethanolic extracts of leaves of the plant in carbon 
tetrachloride-induced liver damage in rats. Hepatotoxicity was induced in rats by i.p. 
injection of CCl4 diluted with olive oil (1:1 v/v; 1 mL/kg body weight) on alternate days 
for 7 days. After 7 days of pretreatment of test extracts, the biochemical markers such as 
Serum Glutamate Oxaloacetate Transaminase (SGOT), Serum Glutamate Pyruvate 
Transaminase (SGPT), Alkaline Phosphatase (ALP), total protein, and albumin were 
estimated followed by the measurement of liver cytosolic antioxidant enzymes such as 
superoxide dismutase, catalase, and peroxidase.The data were analyzed using one-way 
analysis of variance (ANOVA) followed by Dunnett’s t-test. The extract both at the doses 
of 200 and 400 mg/kg p.o. significantly (P < 0.001) reduced the elevated levels of SGPT, 
SGOT, ALP and increased the reduced levels of total protein and albumin compared to 
the CCl4 -treated animals. The extracts also showed a significant (P < 0.001) increase in 
the reduced levels of superoxide dismutase (SOD), catalase, and peroxidase. The effects 
of the extracts on these parameters were comparable with those of the standard, 
silymarin. The findings of the study indicate that the leaf extract of Premna esculenta 
showed a potential hepatoprotective activity and the protective action might have 
manifested by restoring the hepatic SOD, catalase, and peroxidase levels. The results 
justify the traditional use of this plant in liver disorders. 
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4. SCOPE AND PLAN OF WORK 
Management of diabetes mellitus is a global problem. Successful treatment is very 
important for preventing or at least delaying the onset of long-term complications. Through 
nature in the form of herbal medicines or drugs with very minimal adverse effect when compared 
to the available synthetic drugs to treat such chronic disease and disorder. Such herbal drugs as 
therapeutic agents are a nature’s boon when compared to the severe adverse effects of the 
allopathic medical practice for diabetes, despite the fact that the search for a complete and 
permanent cure for the disease is being pursued uncompromisingly by eluding physicians and 
researchers. 
 These herbal remedies which exemplifies the process of symbiosis still remains 
unfamiliar to the up to data technical advances, which has fashioned a marvelous scope for folk 
lore or traditional medicine. it is supposed that the traditional medicines used for the treatment of 
diabetes mellitus satisfy the sequence of complications of the disease. 
Even through the traditional medicinal plant are used to cure the disease from human 
origin, scientific validation of such medicinal plants are necessary and also a scientific research 
to prove its pharmacological and therapeutic efficacy is became vital part. The rummage around 
for the efficient herbal drugs for the treatment of diabetes based on ethno medical clues still 
continuous and in the extended spirit it has yield us very useful herbal remedies on such basis to 
prove the ethno medicinal use of such traditional systems of medicine in India for the treatment 
of diabetes mellitus. So we wish to establish its anti-diabetic property. 
 
 
 
 
 
 
 
 
PLAN OF WORK 
The following in-vitro and in-vivo biochemical markers studies and histopathology of tissue 
were done with of ethanolic root extract of Premna corymbosa Rottl. 
 Collection of plant materials. 
 Authentication of plant materials. 
 Extraction of plant material using Soxhlet apparatus. 
 Determination of phytochemical constituents present in the extract. 
 Pharmacological activities. 
 Anti-diabetic screening models:- 
 Streptozotocin - Nicotinamide induced diabetes in experimental animals. 
 Parameters observed and biochemical evaluation 
 Blood Glucose Level 
 Liver function tests 
 Renal function tests 
 Lipid Profile 
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5. MATERIALS AND METHODS 
5.1 Plant materials 
Roots of Premna  corymbosa was collected from Kolli hills, Namakkal District, Tamil 
Nadu, India and authenticated by Dr R. Duraisami, Professor and Head, Department of 
Pharmacognosy, Nandha College of Pharmacy, Erode, Tamil Nadu, India. Voucher specimens 
(PC/0220/06) were deposited at our College Museum for future reference.  
5.2 Preparation of the extract 
The powdered material of roots of Premna corymbosa was extracted separately using 
70% ethanol by Soxhlet apparatus (Harold varley et al., 1983). The extracts were dried under 
reduced pressure. The dried extract (24.8 g) was stored in desiccator and was subjected to 
various chemical tests to detect the presence of different phyto-constituents like alkaloids, 
tannins, cardiacglycosides and traces of flavonoids etc. 
5.3 Preliminary phytochemical screening 
The ethanolic extract of roots of Premna corymbosa Rottl were subjected to preliminary 
screening for various active phytochemical constituents (Evans WC. 1989) by the following 
tests. 
1) Test for Alkaloids:- 
The extract was treated with dilute hydrochloric acid and filtered. The filtrate is used for 
the following tests. 
a) Mayer’s reagent (Potassium Mercuric Solution) 
0.5 ml of the extract was treated with Mayer’s reagent and the appearance of cream color 
indicates the presence of alkaloid. 
 
 
 
 
 
b) Dragendroff’s test (Potassium Bismuth Iodide) 
0.5 ml of the extract was treated with Dragendroff’s reagent and the appearance of 
reddish brown color precipitate indicates the presence of alkaloid. 
c)Wagner’s test(Iodine-Potassium Iodide Solution) 
0.5ml of the extract was treated with Wagner’s test and the appearance of brown color 
precipitate indicates the presence of alkaloid. 
d) Hager’s test (Saturated solution of picric acid) 
0.5ml of the extracts was treated with Hager’s test and the appearance of yellow color 
precipitate indicates the presence of alkaloid. 
2) Test for Tannin’s:- 
a) The extract was treated with 10% lead acetate solution. The appearance of white 
precipitate indicates the presence of tannins. 
b) The extract was treated with aqueous bromine solution. The appearance of white 
precipitate indicates the presence of tannins. 
3) Test for Flavonoid’s:- 
a)Alkaline Reagent Test  
The extract was added few drops of NaOH solution. Intense of yellow color was formed 
which turns to colourless on addition of few drops of dilute acid indicated the presence of 
flavonoids. 
b) Zinc Hydrochloride Test  
The extract solution added mixture of zinc dust and concentrated Hcl it gives red colour after 
few minute indicates the presence of flavonoids. 
 
 
 
 
c) Shinoda’s Test 
The extracts were dissolved in alcohol, to that one piece of magnesium is added followed 
by concentrated hydrochloric acid along the sides of the test tube drop wise. It is heated in a 
boiling water bath for few minutes. The appearance of magenta colour indicates the presence of 
flavanoids. 
4) Test for cardiac glycosides:- 
Crude extract (2-5 ml) was mixed with 2 ml of glacial acid containing 1-2 drops of 2% 
solution of ferric chloride; the mixture was then poured in to another test tube containing 2 ml of 
concentrated sulfuric acid. A brown ring of a deoxy-sugar, characteristic of alcoholic 
cardinolides at the interface indicated the presence of cardiac glycosides. 
5.4 Pharmacological Screening 
5.4.1 Experimental Animals & Ethical Consideration 
Male wistar albino rats, 9-12 weeks old with average weight of 150-180 g were 
purchased fromthe animal house, Nandha college of pharmacy, Erode, Tamil Nadu, India and 
used for the study. They were housed in polypropylene cages and fed with standard chow diet 
and water ad libitum. The animals were exposed to alternate cycle of 12 h of darkness and light 
each. Before each experiment, the animals were fasted for at least18h. The experimental 
protocols were approved by Institutional Animal Ethics Committee (Regd. No. 
688/PO/re/S/02/CPCSEA) and were in accordance with IAEC. 
 
 
 
 
 
 
 
 
5.5 Drug Treatment 
5.5.1Acute toxicity studies 
The animals were divided into six groups separately and were treated orally with 
ethanolic extracts of roots of Premna corymbosa rottl at a doses of 50, 300, 500, 1000 and 2000 
mg/kg b.w. The animals were continuously observed for 1 hr., then frequently for 14 days. The 
animals were observed continuously for the initial 4 h and intermittently for the next six hour and 
then again at 24h and 48h following drug administration. The parameters observed were 
grooming, hyperactivity, sedation, loss of righting reflex, respiratory rate and convulsion (Ghosh 
M. 1994). 
5.5.2 Estimation of blood glucose levels: 
        Blood was collected from tip of the tail vein and fasting blood glucose levels were 
measured using a commercial glucometer and glucose-oxidase strips (One touch glucometer). 
5.5.3 Streptozotocin-nicotinamide induced diabetic rats 
This model uses concurrent administration of nicotinamide to afford partial protection of 
β-cells against STZ (Masiello et al., 1998). It is based on the work of Junod et al., (1969), who 
systematically investigated the early demonstration (Schein et al., 1967) that nicotinamide 
protected against the diabetogenic effect of STZ. This regimen produces a model of insulin-
deficient, but not insulin-resistant, T2D, characterized by stable, moderate hyperglycemia, 
associated with 60% loss of β-cell function (Masiello et al., 1998; Ghasemi et al., 2014). 
 
 
 
 
 
 
 
 
Requirements and Chemicals 
Wistar albino rats: 150 to 200 g, 8 to 10 weeks old; 
Nicotinamide (Sigma) 
0.9% (w/v) Sodium chloride 
50 mM Sodium citrate buffer (enzyme grade; Fisher), pH 4.5: prepared immediately 
before use 
Streptozotocin (STZ; Sigma) 
1-ml syringes 
23- and 25-G needles 
One Touch Basic blood glucose monitoring system (Lifescan) 
Prepare Animals 
1. At least 5 days prior to the start of the experiment, house two to five male rats per cage 
at 24°C ± 1°C and 55% ± 5% humidity, with a 12-hour light-dark cycle (light on at 8:00 and off 
at 20:00). Allow the rats to have free access to food and water. (Males are generally preferred for 
these studies, as female rats are less sensitive to STZ. While the protocol is designed to minimize 
variability, it is recommended that group sizes number 6 animals each. This allows for the 
morbidity and variance generally associated with these studies. Usually >80% of STZ-injected 
rats develop diabetes under this protocol). 
2. Weigh all rats accurately to 1 g, and randomly divide them into control and 
experimental groups. (The number of rats should be the same in each group). 
3. On experimental day 1, fast all rats for 6 to 8 hr (from 7:00 to 13:00-15:00) prior to 
STZ treatment. Provide water as normal. 
 
 
 
 
Induction of Diabetes with STZ and Nicotinamide 
 Dissolve nicotinamide in 0.9% sodium chloride solution to a concentration of 230mg/ml. 
Weigh 32.5 mg STZ into a 1.5 ml micro centrifuge tube and cover the tube with aluminium foil; 
use one tube for each rat. Prepare the citrate buffer. 
 Using a 1-ml syringe and a 23-G needle, inject nicotinamide i.p. (Donovan and Brown, 
2006 a) at a dose of 230 mg/kg (1.0 ml/kg). 
(The nicotinamide injection must be made 15 min before the i.v. administration of 
streptozotocin). 
Immediately prior to injection, dissolve STZ in the 50 mM sodium citrate buffer, (pH 4.5 
(see step 5), to a final concentration of 32.5 mg/ml. 
(The STZ solution should be prepared fresh for each injection and administered within 
5min of dissolution). 
Using a 1-ml syringe and 25-G needle, inject the STZ solution i.p.                        
(Donovan and Brown, 2006 a) at 65 mg/kg (2.0 ml/kg) for the experimental group. The control 
animals receive an injection of an equal volume of citrate buffer (pH 4.5) only and return the rats 
to their cages. Provide normal food and drinking water. At around 8:00 a.m. on experimental day 
10, test the blood glucose level from a tailvein blood sample (Donovan and Brown, 2006 b) 
using a One Touch Basic blood glucose monitoring system (Brian L.Furman 2015) after 
injection the animals had free access to food and water and were given 5% glucose in their 48h 
after streptozotocin administration, blood samples were drawn from tail and glucose levels 
determined to confirm diabetes.  
The rats were divided into 5 groups as follows, Group I served as normal control which 
received vehicle, Group II served as diabetic control, Group III & IVserved as tests group, 
received 200 & 400 mg/kg b.w. of ethanolic extract of Premna corymbosa rottl respectively 
whereas Group V served as standard which received Glibenclamide (5mg/kgb.w.). The treatment 
was continued daily for 21 days and the blood was collected from the tail for blood glucose 
estimation.  
 
 
Group I- Normal control animals treated with 1% CMC. 
Group II - Diabetic control animals treated with Streptozotocin (65 mg/kg, i.p)  
Group III –Test animals treated with Streptozotocin (65 mg/kg, i.p) and treated with low      dose 
of EEPC 200mg/kg b.w/ p.o. 
Group IV -Test animals treated with Streptozotocin(65 mg/kg, i.p) and treated with low      dose 
of EEPC 400mg/kg b.w/ p.o. 
Group V- Standard animals treated with streptozotocin (65mg/kg, i.p) and treated with 
Glibenclamide 0.5mg/kg b.w/p.o. 
The above mentioned treatment schedule was followed for the respective group of 
animals for 21 days. Blood samples were collected from tail vein in animals on                            
0, 3, 7, 14 & 21
st
 day to estimate blood glucose levels using a commercial glucometer and 
glucose-oxidase strips. (One touch glucometer). 
5.6 BIOCHEMICAL STUDIES: 
At the end of the study, the blood samples were  collected by bleeding of retero-orbital 
plexus using micro capillary technique from all the groups of rats and serum was separated to 
study biochemical parameters such as liver parameters (AST,ALP, ALT), Renal function tests 
(serum creatinine and blood urea) and lipid profile (Total cholesterol, Triglycerides, HDL, 
LDL,VLDL).  
5.6.1 Biochemical parameters: 
a)     Estimation of serum triglycerides. 
Principle: 
 Lipoprotein lipase hydrolyses triglycerides to glycerol and free fatty acids. The glycerol 
formed with ATP in the presence of glycerol kinase forms glycerol 3 phosphates which is 
oxidized by the enzyme glycerol phosphate oxidase to form hydrogen peroxide. The hydrogen 
peroxide further reacts with phenolic compound and 4-aminoantipyrine by the catalytic action of 
 
 
peroxidase to form a red colored quinoneimine dye complex. Intensity of the color formed is 
directly proportional to the amount of triglycerides present in the sample. 
Triglycerides kit consists of LI (triglyceride reagent) and S (triglyceride standard) 
200mg/dl. 
Procedure: 
0.01ml of sample was mixed with 1.0 ml of working reagent and incubated at 35
0
C for 
5min. measured the absorbance of the standard and test sample at 505nm at a light path of 1cm 
against the blank,within 60 min. 
Triglycerides in mg/dl=Abs.T/Abs.S X 200 
b) Estimation of Serum total cholesterol. 
Principle: 
Cholesterol esterase hydrolysis esterified cholesterol to free cholesterol. The free 
cholesterol is oxidized to from hydrogen peroxide which further reacts with phenol and 4-
aminoantipyrine by the catalytic action of peroxidase to form a red colored quinoneimine dye 
complex. Intensity of the color formed is directly proportional to the amount of cholesterol 
present in the sample. 
Cholesterol kit has LI reagent(cholesterol reagent) and Standard  
Cholesterol(200mg/dl) 
Procedure: 
0.01ml sample was mixed with 1.0 ml of cholesterol reagent and incubated at 35
0
C  
5min. measured the absorbance of the standard and test at 505nm at a light path of 1cm against 
the blank,within 60 min. 
 
 
 
 
Calculation: 
Serum total cholesterol (mg/dl)=absorbance of test  × conc. of standard. 
absorbance of standard  
c) Estimation of serum High-Density Lipoprotein Cholesterol. 
Principle: 
The principle behind the HDL estimation lies in precipitating the serum VLD and LDL. 
When the serum is reacted with the polyethylene glycol contained in the precipitating reagent, all 
the VLDL and LDL are precipitated. The HDL remains in the supernatant and is then assayed as 
a sample of cholesterol using the cholesterol reagent.HDL kit has LI, L2 (enzyme reagent), L3 
(precipitating reagent) and HDL cholesterol standard (25mg/dl) 
Working reagent:L1 (4 parts): L2 (1 part) 
Procedure: 
Precipitation of VLDL and LDL: 
0.1ml of sample was mixed with 0.1 ml of precipitating reagent. Incubated at room 
temperature for 5 min. centrifuged at 2500-3000 rpm to obtain a clear supernatant. 
HDL assay: 
0.05 ml of sample was mixed with 1.0 ml of working reagent and incubate at 35
0
 C for 
5min. measure the absorbance of the Standard and test sample at 505nm at a light path of 1cm 
against the blank, within 60 min. 
 
 
 
 
 
 
HDL Cholesterol in mg/dl=Abs.T/Abs. S X 25 X2 
(Where 2 is the dilution factor due to the deproteinization step) 
Calculation of LDL cholesterol (mg/dl) = total cholesterol – (Triglycerides/5)- HDL cholesterol 
d) Estimation of serum Low- Density Lipoprotein Cholesterol (LDL-C) 
Using the data obtained including total cholesterol, HDL cholesterol and VDL, the LDL 
cholesterol levels were calculated using the empirical equation of Friede Wald 
Calculation: 
Serum LDL cholesterol = total cholesterol- (Triglyceride-HDL cholesterol) 
                                                                                                5 
e) Estimation of Serum Glutamate Oxaloacetate Transaminase- SGOT 
Principle: 
Between L-Aspartate and SGOT catalyzes the transfer of amino group between L-
Aspartate and alpha Ketoglutarate to form oxaloacetate and glutamate. The oxaloacetate formed 
reacts with NADH in the presence of malate Dehydrogenase to form NAD. The rate of oxidation 
of NADH to NAD is measured as a SGOT kit contains L1 (enzyme reagent) and L2 (Starter 
reagent). 
Procedure: 
Substrate start assay: 
0.1ml of sample was mixed with 0.8 ml of enzyme reagent and incubated at 35
0
 C for 1 
min and added 0.2 ml of starter reagent. Mixed well and read the initial absorbance change per 
minute (∆A/min). 
 
 
 
 
Sample start assay: 
1.0ml of working reagent is incubated at 35
0
 C for 1 min and added 0.1 ml of starter 
reagent. Mixed well and read the initial absorbance A0 and repeat the absorbance reading after 
every 1,2 and 3 min. calculate the mean absorbance changer per minute (∆A/min). 
SGOT (ASAT) activity in U/L =∆A/min X 1546 
f) Estimation of serum SGPT. 
Principle: 
SGPT catalyzes the transfer of amino group between L-Alanine and α Ketoglutarate to 
form pyruvate and glutamate. The pyruvate formed reacts with NADH in the presence of lactate 
Dehydrogenase to form NAD. The rate of oxidation of NADH to NAD is measured as a decrease 
in absorbance which is proportional to the SGPT activity in the sample. 
SGPT kit contains L1 (Enzyme reagent) L2 (Starter reagent) 
Procedure: 
Substrate start assay: 
0.1ml of sample was mixed with 0.8 ml of enzyme reagent and incubated at 35
0
 C for 1 
min and added 0.2ml of starter reagent. Mixed well and read the initial absorbance A0 and 
repeat the absorbance reading after every 1, 2 and 3 min. calculate the mean absorbance 
change per minute (∆A/min). 
Sample start assay: 
 1.0ml of working reagent is incubated at 35
0
 C for 1 min and adds 0.1 ml of starter 
reagent. Mix well and read the initial absorbance A0 and repeat the absorbance reading after 
every 1, 2, and 3 min. calculate the mean absorbance change per minute(∆A/min). 
SGPT (ALAT) activity in U/L = ∆A/min X 1546 
 
 
 
g) Estimation of creatinine ( Modifiedjaffe’s Kinetic method) 
Serum creatinine levels were estimated by using test kit. 
h) Estimation of Urea: 
Serum Urea levels were estimated by using test kit. 
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6. RESULTS 
6.1 PHARMACOGNOSTICAL STUDY 
6.1.1 Qualitative Determination 
 The qualitative determinations of the ethanolic extract of root of  Premna corymbosa rottl 
were shown in Table No.1. In qualitative determination, the Phytoconstituents analysis was 
performed and which confirms the presence of alkaloids, glycosides, flavonoids and tannins. 
Table No. 1. Phytoconstituents analysis of ethanolic root extract of  Premna corymbosa rottl 
S.No. Plant constituents Premna corymbosa rottl 
1 Test for alkaloids + 
2 Test for glycosides + 
3 Test for carbohydrates - 
4 Test for phytosterols - 
5 Test for sterols - 
6 Test for flavonoids + 
7 Test for saponins - 
8 Test for tannins + 
9 Test for terpenoids - 
10 Test for fixed oils and fats - 
 -  Absent,   Present 
 
 
 
 
 
 
 
 
 
6.2. Acute Toxicity Studies 
 This study helps us to determine the therapeutic index and the extract was confirmed to 
be safe. Acute toxicity study was performed as per the OECD guidelines. The extracts were 
administered orally at a doses of 50, 300, 500, 1000 and 2000mg/kg b.w. in 0.5%                        
carboxy methyl cellulose (CMC). No gross observational changes were recorded during the 
period of 14 days observation.  
 
Table No. 2. The effects of ethanolic root extract of Premna corymbosa rottl on general 
behavioral observation in acute toxicity studies 
S.No. General Behaviour Observation after drug administration 
1 Sedation + 
2 Hypnosis - 
3 Convulsion - 
4 Ptosis - 
5 Analgesia - 
6 Stupar reaction - 
7 Motor activity - 
8 Muscle relaxant - 
9 CNS stimulant + 
10 CNS depressant - 
11 Pilo erection - 
12 Skin colour - 
13 Lacrimation - 
14 Stool consistency - 
 -  Absent,   Present 
 
 
 
 
 
6.3 Pharmacological Studies 
6.3.1 Antidiabetic Activity 
The blood glucose level increased significantly in STZ and nicotinamide treated group when 
compared to control group. The STZ and nicotinamide induced rats were treated with the 
ethanolic root extract of Premna corymbosa rottl 200mg/kg /p.o and 400mg/kg/p.o for the 
duration of 21 days. Treatment with ethanolic root extract of Premna corymbosa rottl at the dose 
of 200 mg/kg/p.o shows marginal reduction in the blood glucose level at second week. Treatment 
with ethanolic root extract of Premna corymbosa rottl at the dose of 400mg/kg/p.o. showed 
significant decrease in the blood glucose level at first week (p<0.01), which further reduced in 
the second, third and fourth weeks (p<0.001), respectively. Treatment with glibenclamide 
(0.5mg/kg b.w/ p.o) produced a significant (p<0.001) decrease in blood glucose level from first 
week to fourth week.  
Table No.3 The effect of ethanolic root extract of Premna corymbosa rottl on blood glucose 
levels in STZ - nicotinamide induced diabetic rats 
Groups 
Treatment/
Dose 
0 day 
(mg/dL) 
After 3days 
(mg/dL) 
After 7 days 
(mg/dL) 
After 14 days 
(mg/dL) 
After 21days 
(mg/dL) 
Normal 
control 
96.32± 
1.12 
95.71± 
0.96*** 
96.08± 
1.35*** 
96.54± 
1.24*** 
98.92± 
0.97*** 
Diabetic 
control 
264.18± 
2.64 
281.06± 
1.98 
271.12± 
2.54 
219.37± 
2.36 
209.14± 
1.97 
EEPC 
(200mg/kg 
b.w.) 
263.16± 
2.91 
247.74± 
2.23** 
208.17± 
3.06** 
176.51± 
3.27** 
130.36± 
2.97** 
EEPC 
(400mg/kg 
b.w.) 
261.49± 
3.82 
221.12± 
3.54** 
160.75± 
2.59*** 
130.50± 
2.89*** 
110.69± 
3.06*** 
Standard 
|Glibencla
mide 
(5mg/kg 
b.w.) 
256.13± 
 3.29 
200.12± 
3.07*** 
152.43± 
2.99*** 
118.74± 
2.86*** 
98.16± 
3.04*** 
Values are expressed as mean ± SEM (n=6). *p<0.05,**p<0.01,***p<0.001Vs control. Statistical significance test 
for comparision was done by one way ANOVA followed by Dunnet’s‘t’ test 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
Figure No.11. Effect of ethanolic root extract of Premna corymbosa rottl on blood glucose level in STZ and 
nicotinamide induced diabetic rats 
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6.3.2 Estimation of liver enzymes 
The effect of ethanolic root extract of Premna corymbosa rottl at doses of 200 & 400 mg/kg b.w. 
on liver enzymes. It was found that the ethanolic root extract of Premna corymbosa rottl showed 
significant (p<0.001) protection on liver parameters. The ethanolic root extract of Premna 
corymbosa rottl has not elevated the normal liver profiles (ALP, AST, and ALT) on dose 
dependent manner. The standard drug glibenclamide (0.5mg/kg/p.o) showed significant 
(p<0.001) protection in ALP,AST,ALT when compared STZ-nicotinamide induced diabetic 
animals.  
 
Table No.4. Effect of Ethanolic root extract of Premna corymbosa on liver profile on STZ-
nicotinamide induced diabetic rats. 
Groups 
Treatment/Dose 
ALP 
(IU/L) 
AST 
(IU/L) 
ALT 
(IU/L) 
Normal control 89.35± 
7.12*** 
83.75± 
7.36*** 
25.52± 
1.65*** 
Diabetic control 168.96± 
9.02 
161.92± 
9.07 
128.37± 
7.92 
EEPC (200mg/kg 
b.w.) 
121.66± 
8.12* 
87.31± 
7.10** 
44.91± 
2.36* 
EEPC 
(400mg/kg b.w.) 
100.99± 
7.96** 
89.18± 
6.87*** 
34.68± 
2.72** 
Standard 
|Glibenclamide 
(5mg/kg b.w.) 
85.94± 
6.06*** 
89.85± 
6.84*** 
28.96± 
1.82*** 
Values are expressed as mean ± SEM (n=6). *p<0.05,**p<0.01,***p<0.001Vs control. Statistical significance test 
for comparision was done by one way ANOVA followed by Dunnet’s ‘t’ test. 
 
 
 
 
 
Figure No.12. Effect of ethanolic root extract of Premna corymbosa on liver profile in 
STZ-nicotinamide induced diabetic rats 
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6.3.3. Estimation of renal profile 
 
The serum urea level was significantly (p<0.001) increased in STZ-nicotinamide induced 
diabetic rats when compared to control rats. Serum urea level of diabetic rat treated with EEPC 
200mg/kg/p.o and 400mg/kg/p.o showed significant decrease (p<0.001) and (p<0.001) in serum 
urea level when compared to STZ- nicotinamide induced diabetic rat. Glibenclamide (0.5mg/kg 
b.w/p.o) treatment showed significant (p<0.001) decrease in serum urea when compared to STZ-
nicotinamide induced diabetic animals.  
 
Table No.5. Effect of ethanolic root extract of Premna corymbosa on renal profile in STZ-
nicotinamide in diabetes induced rat 
Groups 
Treatment/Dose 
Serum Creatinine (mg/dl) Blood Urea (mg/dl) 
Normal control 1.18± 
0.08*** 
25.73± 
2.26*** 
Diabetic control 2.58± 
0.16 
41.14± 
2.61 
EEPC (200mg/kg b.w.) 1.42± 
0.12** 
30.61± 
2.84* 
EEPC 
(400mg/kg b.w.) 
1.32± 
0.09*** 
27.86± 
2.51** 
Standard |Glibenclamide 
(5mg/kg b.w.) 
1.27± 
0.10*** 
23.94± 
2.08*** 
Values are expressed as mean ± SEM (n=6). *p<0.05,**p<0.01,***p<0.001Vs control. Statistical significance test 
for comparision was done by one way ANOVA followed by Dunnet’s ‘t’ test. 
 
 
 
 
 
 
 
 
 
 
Figure No.13. Effect of ethanolic root extract of Premna corymbosa on renal profile in STZ-nicotinamide 
induced diabetic rats 
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6.3.4 Estimation of lipid profile 
The serum total cholesterol, triglyceride,LDL,VLDL level was significantly increased whereas 
HDL was significantly decreased in STZ-nicotinamide induced diabetic rat when compared to 
control rats. Serum total cholesterol, triglyceride, LDL, VLDL level of diabetic animal treated 
with EEPC 200mg/kg/p.o and 400mg/kg/p.o showed significant decrease (p<0.001) and HDL 
level of diabetic animal treated with EEPC showed significant increase (p<0.01), when compared 
to STZ-nicotinamide induced diabetic animals. Glibenclamide(0.5mg/kg/p.o) also showed a 
significant decrease (p<0.001) in serum total cholesterol ,triglyceride, LDL,VLDL level and 
HDL was significantly increased when compared to STZ-nicotinamide induced diabetic rat. 
Table No 6: Effect of ethanolic root extract of Premna corymbosa on lipid profile in   STZ-
nicotinamide induced diabetic rats\ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are expressed as mean ± SEM (n=6). *p<0.05,**p<0.01,***p<0.001Vs control.  Statistical significance test 
for comparision was done by one way ANOVA followed by Dunnet’s ‘t’ test. 
 
Groups 
Treatment/ 
Dose 
Total 
cholesterol 
(mg/dl) 
 
Triglycerides 
(mg/dl) 
 
HDL 
(mg/dl) 
 
LDL 
(mg/dl) 
 
VLDL 
(mg/dl) 
 
Normal control 66.68± 
1.95*** 
34.32± 
1.72*** 
13.75± 
0.82*** 
59.62± 
3.16*** 
6.85± 
0.22*** 
Diabetic 
control 
77.61± 
1.56 
44.11± 
2.16 
12.21± 
0.95 
74.25± 
2.94 
9.49± 
0.30 
EEPC 
(200mg/kg 
b.w.) 
71.74± 
1.47** 
36.33± 
1.94** 
15.16± 
0.82* 
64.35± 
3.32** 
7.88± 
0.28* 
EEPC 
(400mg/kg 
b.w.) 
68.18± 
1.78*** 
35.53± 
2.21*** 
14.08± 
0.91*** 
63.35± 
2.68*** 
7.09± 
0.32** 
Standard 
|Glibenclamide 
(5mg/kg b.w.) 
67.41± 
3.23*** 
35.64± 
2.62*** 
14.30± 
0.76*** 
63.25± 
2.94*** 
7.50± 
0.28*** 
 
 
 
 
 
  
Figure No.14. Effect of ethanolic root extract of Premna corymbosa on serum total cholesterol, 
triglycerides,LDL,HDL,VLDL in STZ- nicotinamide induced diabetic rats. 
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DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. DISCUSSION 
Medicinal plants due to their natural origin plays a major role in treatment of diabetes, 
especially who have limited resources. Report of ethnobotany revealed that about 800 medicinal 
plants have anti diabetic activity(I-4) and their respective phytochemical constituents have 
alkaloids, glycosides, terpenoids, flavonoids etc are very effective in both preclinical and clinical 
studies (I-5,6). The present investigation showed that the ethanolic extract of premna corymbosa 
is nontoxic by oral route in wistar albino rats, up to a maximum of 2000mg/kg b.w acutely. 
Literature review and phytochemical evaluation showed that presence of flavonoids, 
alkaloids, glycosides, sterols.It is possible that the anti diabetic property of ethanolic extract of 
Premna corymbosa could be mediated by the synergistic effect of these phytochemicals.The STZ 
induced diabetic model is one of the best model in which  Streptozotocin  is an alkylating agent 
which causes DNA damage which results in the activation of poly(ADP-ribose) synthetase that 
leads to the depletion of NAD and ATP virtually causes beta cell necrosis in the experimental 
rats. It leads to a reduction in insulin release there by a drastic reduction in plasma insulin 
concentration leading to stable hyper glycemic state. STZ is the most commonly used chemical 
for the induction of experimental diabetes for both IDDM and NIDDM. 
The present study was conducted to evaluate the anti diabetic potential of                        
Premna corymbosa in normal as well as STZ-nicotinamide induced diabetic rat. The study 
indicated that the ethanolic extract of Premna corymbosa possess blood glucose lowering 
property in STZ –nicotinamide induced diabetic rats. Oral administration of ethanolic extract of                              
Premna corymbosa protected against STZ –nicotinamide induced diabetes mellitus.  
The normal level blood urea and serum creatinine indicates that the ethanolic extract of 
Premna corymbosa did not interfere with the renal function and renal integrity was preserved 
and also there were no significant abnormalities.The study also revealed that there were no 
significant changes inliver function tests. The ethanolic extract of Premna corymbosa does not 
affect the normal values of ALP, AST, ALT and it confirmsthat the extract doesn’t have any 
hepatotoxic nature.The study also reveals that the ethanolic extract of Premna corymbosa does 
not affect the lipid profile such as triglycerides, total cholesterol, HDL, LDL, and VLDL.  
 
 
 
 
 
 
 
 
 
SUMMARY AND CONCLUSION 
 
 
 
 
 
 
 
 
 
 
8. SUMMARY AND CONCLUSION 
Several factors underlie the growing popularity of herbal treatments for a variety of 
chronic conditions. Interestingly, people who utilize alternative therapies are not necessarily 
uniformed. Many people using herbal medicines find the health care alternatives are more 
congruent with their own values, beliefs and philosophical orientation towards health and life. 
The root of Premna corymbosa was selected for the evaluation of antidiabetic potential in 
STZ-nicotinamide induced diabetic rat model.The  root extract was extracted by hot percolation 
using ethanol as a solvent in soxhlet apparatus and the preliminary phytochemical screening was 
performed and it shows that the ethanolic root extract of Premna corymbosa contains alkaloids, 
glycosides, flavonoids and tannins. 
Safety profile is essential for the drugs obtained from the plant origin. The level of 
toxicity can be evaluated by toxicological studies.From the results it was concluded that the 
ethanolic root extract of Premna corymbosa showed significant anti diabetic activity in a dose 
dependant manner compared to the standard drug glibenclamide.  
The result also showed significantdecrease in the liver Alkaline phosphatase(ALP), 
Aspartate amino transferase(AST), Alanine amino transferase(ALT), serum urea level, 
cholesterol, triglycerides, VLDL and LDL  was  in STZ-nicotinamide induced diabetic animals 
when compared to control group. It is concluded that ethanolic root extract of Premna 
corymbosa showed significant effect in STZ-nicotinamide induced diabetic rats. Further studies 
are necessary to examine the underlying mechanism of hypoglycemic effect and to isolate the 
active compound (s) responsible for antidiabetic activities. 
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